Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sulphonylureas are an accepted and widely used treatment for hyperglycaemia in type 2 diabetes. The UK Prospective Diabetes Study (UKPDS) demonstrated that, like other oral agents used in clinical practice, there are early good results which fail over time. Conclusions drawn show that it is in fact a result of progressive loss of beta-cell function. Results from the UKPDS and several other studies reinforce the need for ongoing and tailored treatment to maintain glycaemic control and slow symptom progression. So sulphonylureas improve beta-cell function in those with type 2 diabetes over many years, but their effects are lessened by progressive beta-cell failure. In the enthusiasm for new therapies they should not be neglected as a mainstay of oral treatment early in the course of type 2 diabetes.

Original publication




Journal article


British Journal of Diabetes and Vascular Disease

Publication Date





192 - 196